pteridines has been researched along with Cancer of Colon in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells." | 7.80 | Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma. ( Abastabar, M; Akbari, A; Amanpour, S; Dehpour, AR; Faghihloo, E; Ghaffari, SH; Ghahremani, MH; Heidari, M; Karimi, A; Khoshzaban, A; Mobini, GR; Muhammadnejad, S; Shidfar, F, 2014) |
| "To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells." | 3.80 | Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma. ( Abastabar, M; Akbari, A; Amanpour, S; Dehpour, AR; Faghihloo, E; Ghaffari, SH; Ghahremani, MH; Heidari, M; Karimi, A; Khoshzaban, A; Mobini, GR; Muhammadnejad, S; Shidfar, F, 2014) |
| "Diploid and tetraploid cells were transfected with siPLK1 or treated with PLK1 inhibitor Bi2536 in combination with spindle poison." | 1.56 | Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1. ( Jemaà, M; Kifagi, C; Massoumi, R; Serrano, SS, 2020) |
| " If this is the case, then prolonged bioavailability in the tumor should significantly increase the efficacy of antimitotic agents." | 1.56 | Calibrated liposomal release of the anti-mitotic agent BI-2536 increases the targeting of mitotic tumor cells. ( Ann Matthews, A; Cheong, I; Goh, SMP; Ng, CZ; Sum, R; Xu, A; Yap, LW, 2020) |
| "Here, we show that tumorigenic colon cancer cells can be found in a rapidly proliferating state in vitro and in vivo, both in human tumors and mouse xenografts." | 1.38 | Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. ( Baiocchi, M; Biffoni, M; De Maria, R; Di Franco, S; Federici, G; Francescangeli, F; Pagliuca, A; Patrizii, M; Ricci Vitiani, L; Signore, M; Todaro, M; Zeuner, A, 2012) |
| " First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high volume of distribution and a long terminal half-life in mice (V(ss) = 7." | 1.35 | BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. ( Adolf, GR; Baum, A; Garin-Chesa, P; Grauert, M; Haslinger, C; Hoffmann, M; Quant, J; Rudolph, D; Steegmaier, M, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jemaà, M | 1 |
| Kifagi, C | 1 |
| Serrano, SS | 1 |
| Massoumi, R | 1 |
| Ng, CZ | 1 |
| Ann Matthews, A | 1 |
| Sum, R | 1 |
| Goh, SMP | 1 |
| Xu, A | 1 |
| Yap, LW | 1 |
| Cheong, I | 1 |
| Lund-Andersen, C | 1 |
| Patzke, S | 1 |
| Nähse-Kumpf, V | 1 |
| Syljuåsen, RG | 1 |
| Akbari, A | 1 |
| Amanpour, S | 1 |
| Muhammadnejad, S | 1 |
| Ghahremani, MH | 1 |
| Ghaffari, SH | 1 |
| Dehpour, AR | 1 |
| Mobini, GR | 1 |
| Shidfar, F | 1 |
| Abastabar, M | 1 |
| Khoshzaban, A | 1 |
| Faghihloo, E | 1 |
| Karimi, A | 1 |
| Heidari, M | 1 |
| Rudolph, D | 1 |
| Steegmaier, M | 1 |
| Hoffmann, M | 1 |
| Grauert, M | 1 |
| Baum, A | 1 |
| Quant, J | 1 |
| Haslinger, C | 1 |
| Garin-Chesa, P | 1 |
| Adolf, GR | 1 |
| Francescangeli, F | 1 |
| Patrizii, M | 1 |
| Signore, M | 1 |
| Federici, G | 1 |
| Di Franco, S | 1 |
| Pagliuca, A | 1 |
| Baiocchi, M | 1 |
| Biffoni, M | 1 |
| Ricci Vitiani, L | 1 |
| Todaro, M | 1 |
| De Maria, R | 1 |
| Zeuner, A | 1 |
6 other studies available for pteridines and Cancer of Colon
| Article | Year |
|---|---|
Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Topics: Antimitotic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Cycle Proteins; C | 2020 |
Calibrated liposomal release of the anti-mitotic agent BI-2536 increases the targeting of mitotic tumor cells.
Topics: Animals; Antimitotic Agents; Cell Proliferation; Colonic Neoplasms; Drug Compounding; Drug Liberatio | 2020 |
PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.
Topics: Bone Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; | 2014 |
Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neopla | 2014 |
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell C | 2009 |
Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Cycle; Cell Cycle Proteins; Cell Growth Processes; Cell L | 2012 |